A novel immune-related microRNA signature for prognosis of thymoma

Aging (Albany NY). 2022 Jun 7;14(11):4739-4754. doi: 10.18632/aging.204108. Epub 2022 Jun 7.

Abstract

Introduction: Immune microenvironment and microRNAs serve as common predictors for diagnosis and prognosis of tumors.

Methods: Expression of 122 genes and 126 microRNAs in thymoma was obtained from TCGA database. The proportion of tumor-infiltrating cells was calculated, and IMRS was constructed. TREM2hi score was calculated before functional enrichment analysis on gene sets.

Results: IMRS3, TREM2hi score, and CD8+ T lymphocyte abundance were significantly different among WHO classifications. WHO classification, Masaoka staging, and miR-130b-5p, miR-1307-3p, miR-425-5p, CD8, CD68, and CCL18 expression were prognostic factors for relapse-free survival and overall survival. IMRS3 upregulation polarized macrophages into M2, which rejected CD8+ T and other effector lymphocytes to promote thymoma malignant progression.

Conclusions: BRRS may present a novel immune-related microRNA signature for TET prognosis.

Keywords: biomarker-related recurrence risk score; immune-related microRNA signature; thymoma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor / genetics
  • Biomarkers, Tumor / metabolism
  • Gene Expression Regulation, Neoplastic
  • Humans
  • MicroRNAs* / genetics
  • MicroRNAs* / metabolism
  • Neoplasm Recurrence, Local / genetics
  • Prognosis
  • Thymoma* / genetics
  • Thymus Neoplasms* / genetics
  • Tumor Microenvironment / genetics

Substances

  • Biomarkers, Tumor
  • MicroRNAs